Pacira BioSciences (PCRX) Capital Expenditures Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 28.56% |
| 10 | Pacira BioSciences | 1.08 Bn | 876.91 Mn | 140.96 Mn | -15.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.43% |
| Dec 31, 2025 | -65.89% |
| Sep 30, 2025 | -9.27% |
| Jun 30, 2025 | -7.31% |
| Mar 31, 2025 | -50.29% |
| Dec 31, 2024 | -50.37% |
| Sep 30, 2024 | 30.38% |
| Jun 30, 2024 | -28.73% |
| Mar 31, 2024 | -64.06% |
| Dec 31, 2023 | -1.69% |
| Sep 30, 2023 | -28.43% |
| Jun 30, 2023 | -78.15% |
| Mar 31, 2023 | -4.62% |
| Dec 31, 2022 | 59.76% |
| Sep 30, 2022 | 48.19% |
| Jun 30, 2022 | 85.79% |
| Mar 31, 2022 | 45.72% |
| Dec 31, 2021 | -2.03% |
| Sep 30, 2021 | -84.16% |
| Jun 30, 2021 | 58.82% |